Gilead likely to drop darusentan on failed Phase III resistant hypertension trial
This article was originally published in Scrip
Executive Summary
Gilead Sciences looks likely to terminate development of endothelin A-receptor antagonist darusentan for resistant hypertension after the drug failed to meet its primary endpoint in a second Phase III trial. The company's share price fell by 3.5% to close at $45.31 on Nasdaq after the failure was announced on December 15th.